{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:21:29Z","timestamp":1761862889908},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T00:00:00Z","timestamp":1257897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00520-009-0778-0","type":"journal-article","created":{"date-parts":[[2009,11,10]],"date-time":"2009-11-10T18:09:50Z","timestamp":1257876590000},"page":"1553-1564","source":"Crossref","is-referenced-by-count":14,"title":["Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index"],"prefix":"10.1007","volume":"18","author":[{"given":"Mu-Tai","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Yih","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu-Pin","family":"Pi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,11]]},"reference":[{"key":"778_CR1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00000421-199106000-00001","volume":"14","author":"DL Ahmann","year":"1991","unstructured":"Ahmann DL, Schaid DJ, Ingle JN, Bisel HF, Schutt AJ, Buckner JC, Long HJ, Rubin J (1991) A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. Am J Clin Oncol 14:179\u2013183","journal-title":"Am J Clin Oncol"},{"key":"778_CR2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00595-006-3261-2","volume":"36","author":"S Asaka","year":"2006","unstructured":"Asaka S, Fujimoto T, Akaishi J, Ogawa K, Onda M (2006) Genetic prognostic index influences patient outcome for node-positive breast cancer. Surg Today 36:793\u2013801","journal-title":"Surg Today"},{"key":"778_CR3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","volume":"14","author":"J Baselga","year":"1996","unstructured":"Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737\u2013744","journal-title":"J Clin Oncol"},{"key":"778_CR4","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(09)60316-0","volume":"373","author":"JR Benson","year":"2009","unstructured":"Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373:1463\u20131479","journal-title":"Lancet"},{"key":"778_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/annonc\/mdl155","volume":"18","author":"S Beslija","year":"2007","unstructured":"Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, K\u00f6stler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H (2007) Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18:215\u2013225","journal-title":"Ann Oncol"},{"key":"778_CR6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.11273","volume":"106","author":"I Bi\u00e8che","year":"2003","unstructured":"Bi\u00e8che I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R (2003) Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106:758\u2013765","journal-title":"Int J Cancer"},{"key":"778_CR7","first-page":"4845","volume":"51","author":"MC Bissery","year":"1991","unstructured":"Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 51:4845\u20134852","journal-title":"Cancer Res"},{"key":"778_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1634\/theoncologist.8-4-335","volume":"8","author":"AU Buzdar","year":"2003","unstructured":"Buzdar AU (2003) Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 8:335\u2013341","journal-title":"Oncologist"},{"key":"778_CR9","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","volume":"19","author":"A Buzdar","year":"2001","unstructured":"Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C (2001) Phase III, multicenter, double blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357\u20133366","journal-title":"J Clin Oncol"},{"key":"778_CR10","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.1996.14.7.2000","volume":"14","author":"A Buzdar","year":"1996","unstructured":"Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 14:2000\u20132011","journal-title":"J Clin Oncol"},{"key":"778_CR11","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bjc.6603347","volume":"95","author":"M Campone","year":"2006","unstructured":"Campone M, Cortes-Funes H, Vorobiof D, Martin M, Slabber CF, Ciruelos E, Bourbouloux E, Mendiola C, Delgado FM, Colin C, Aslanis V, Fumoleau P (2006) Vinflunine: a new active drug for second-line line treatment of advanced breast cancer. Results of Phase II and pharmacokinetic study in patients progressing after first-line anthracycline\/taxane-based chemotherapy. Br J Cancer 95:1161\u20131166","journal-title":"Br J Cancer"},{"key":"778_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3816\/CBC.2009.n.007","volume":"9","author":"SM Campos","year":"2009","unstructured":"Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA (2009) A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 9:39\u201344","journal-title":"Clin Breast Cancer"},{"key":"778_CR13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H","volume":"63","author":"CL Carter","year":"1989","unstructured":"Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181\u2013187","journal-title":"Cancer"},{"key":"778_CR14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ijrobp.2005.11.015","volume":"64","author":"SH Cheng","year":"2006","unstructured":"Cheng SH, Horng CF, Clarke JL, Tsou MH, Tsai SY, Chen CM, Jian JJ, Liu MC, West M, Huang AT, Prosnitz LR (2006) Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys 64:1401\u20131409","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"778_CR15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","volume":"9","author":"M Cianfrocca","year":"2004","unstructured":"Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9:606\u2013616","journal-title":"Oncologist"},{"key":"778_CR16","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639\u20132648","journal-title":"J Clin Oncol"},{"key":"778_CR17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.12-3-253","volume":"12","author":"M Colozza","year":"2007","unstructured":"Colozza M, De Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F (2007) Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12:253\u2013270","journal-title":"Oncologist"},{"key":"778_CR18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0959-8049(00)00435-4","volume":"37","author":"G D'Eredita'","year":"2001","unstructured":"D'Eredita' G, Giardina C, Martellotta M, Natale T, Ferrarese F (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37:591\u2013596","journal-title":"Eur J Cancer"},{"key":"778_CR19","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","volume":"26","author":"A Leo Di","year":"2008","unstructured":"Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544\u20135552","journal-title":"J Clin Oncol"},{"key":"778_CR20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp060352","volume":"65","author":"E Dobbe","year":"2008","unstructured":"Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM (2008) Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. Am J Health Syst Pharm 65:23\u201328","journal-title":"Am J Health Syst Pharm"},{"key":"778_CR21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1998.16.2.453","volume":"16","author":"P Dombernowsky","year":"1998","unstructured":"Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453\u2013461","journal-title":"J Clin Oncol"},{"key":"778_CR22","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1158\/1078-0432.CCR-08-0974","volume":"14","author":"M Dowsett","year":"2008","unstructured":"Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14:8019\u20138026","journal-title":"Clin Cancer Res"},{"key":"778_CR23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/jnci\/85.15.1206","volume":"85","author":"G Gasparini","year":"1993","unstructured":"Gasparini G, Pozza F, Harris AL (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206\u20131219","journal-title":"J Natl Cancer Inst"},{"key":"778_CR24","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"778_CR25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","volume":"14","author":"PA Greenberg","year":"1996","unstructured":"Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197\u20132205","journal-title":"J Clin Oncol"},{"key":"778_CR26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.1992.10.7.1049","volume":"10","author":"BA Gusterson","year":"1992","unstructured":"Gusterson BA, Gelber A, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R (1992) Prognostic importance of c-erb-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049\u20131056","journal-title":"J Clin Oncol"},{"key":"778_CR27","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287\u20135312","journal-title":"J Clin Oncol"},{"key":"778_CR28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","volume":"12","author":"MJ Hayat","year":"2007","unstructured":"Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12:20\u201337","journal-title":"Oncologist"},{"key":"778_CR29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1023\/A:1006197805041","volume":"52","author":"DF Hayes","year":"1998","unstructured":"Hayes DF, Trock B, Harris AL (1998) Assessing the clinical impact of prognostic factors: when is \u201cstatistically significant\u201d clinically useful? Breast Cancer Res Treat 52:305\u2013319","journal-title":"Breast Cancer Res Treat"},{"key":"778_CR30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1983.1.12.776","volume":"1","author":"GN Hortobagyi","year":"1983","unstructured":"Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU, Blumenschein GR (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1:776\u2013786","journal-title":"J Clin Oncol"},{"key":"778_CR31","first-page":"33","volume":"32","author":"HC Hsu","year":"2009","unstructured":"Hsu HC, Chang HK, Lin YC, Hseu S, Chen JS, Yang TS, Wang HM, Shen WC (2009) The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. Chang Gung Med J 32:33\u201341","journal-title":"Chang Gung Med J"},{"key":"778_CR32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1634\/theoncologist.2007-0246","volume":"13","author":"CS Huang","year":"2008","unstructured":"Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang KJ (2008) The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I\u2013II and operable stage III breast cancers. Oncologist 13:751\u2013760","journal-title":"Oncologist"},{"key":"778_CR33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0959-8049(95)00014-3","volume":"32A","author":"W Jonat","year":"1996","unstructured":"Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404\u2013412","journal-title":"Eur J Cancer"},{"key":"778_CR34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CBC.2008.n.025","volume":"8","author":"SE Jones","year":"2008","unstructured":"Jones SE (2008) Metastastic breast cancer: the treatment challenge. Clin Breast Cancer 8:224\u2013233","journal-title":"Clin Breast Cancer"},{"key":"778_CR35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-008-0081-7","volume":"116","author":"RL Jones","year":"2009","unstructured":"Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116:53\u201368","journal-title":"Breast Cancer Res Treat"},{"key":"778_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","volume":"9","author":"F Kassam","year":"2009","unstructured":"Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9:29\u201333","journal-title":"Clin Breast Cancer"},{"key":"778_CR37","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","volume":"18","author":"M Kaufmann","year":"2000","unstructured":"Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. The Exemestane Study Group. J Clin Oncol 18:1399\u20131411","journal-title":"J Clin Oncol"},{"key":"778_CR38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","volume":"19","author":"JG Klijn","year":"2001","unstructured":"Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343\u2013353","journal-title":"J Clin Oncol"},{"key":"778_CR39","doi-asserted-by":"crossref","unstructured":"Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP (2009) The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol (in press)","DOI":"10.1016\/j.critrevonc.2009.04.011"},{"key":"778_CR40","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/sj.bjc.6604769","volume":"99","author":"AK Koutras","year":"2008","unstructured":"Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G, Hellenic Cooperative Oncology Group (HeCOG) (2008) Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 99:1775\u20131785","journal-title":"Br J Cancer"},{"key":"778_CR41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/sj.bjc.6604898","volume":"100","author":"WH Kuo","year":"2009","unstructured":"Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS (2009) Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 100:563\u2013570","journal-title":"Br J Cancer"},{"key":"778_CR42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2006.06.4220","volume":"25","author":"NL Liberato","year":"2007","unstructured":"Liberato NL, Marchetti M, Barosi G (2007) Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 25:625\u2013633","journal-title":"J Clin Oncol"},{"key":"778_CR43","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1200\/JCO.1993.11.8.1536","volume":"11","author":"PP Lin","year":"1993","unstructured":"Lin PP, Allison DC, Wainstock J et al (1993) Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 11:1536\u20131544","journal-title":"J Clin Oncol"},{"key":"778_CR44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jjco\/hyl124","volume":"37","author":"YC Lin","year":"2007","unstructured":"Lin YC, Chang HK, Chen JS, Wang HM, Yang TS, Liaw CC (2007) A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol 37:23\u201329","journal-title":"Jpn J Clin Oncol"},{"key":"778_CR45","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1158\/1055-9965.EPI-09-0096","volume":"18","author":"CH Lin","year":"2009","unstructured":"Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL (2009) Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 18:1807\u20131814","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"suppl 18","key":"778_CR46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/jco.2006.24.18_suppl.517","volume":"24","author":"H Lueck","year":"2006","unstructured":"Lueck H, Minckwitz GV, Du Bois A, Schrader I, Huober J, Heilmann V, Beckmann M, St\u00e4hle A, Jackisch C, Marth C, Richter B (2006) Epirubicin\/paclitaxel (EP) vs. capecitabine\/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 24(suppl 18):517","journal-title":"J Clin Oncol"},{"key":"778_CR47","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Ant\u00f3n A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23:4265\u20134274","journal-title":"J Clin Oncol"},{"key":"778_CR48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10434-000-0416-z","volume":"7","author":"DR McCready","year":"2000","unstructured":"McCready DR, Chapman JA, Hanna WM, Kahn HJ, Murray D, Fish EB, Trudeau ME, Andrulis IL, Lickley HL (2000) Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol 7:416\u2013426","journal-title":"Ann Surg Oncol"},{"key":"778_CR49","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/modpathol.3800114","volume":"17","author":"DV Miller","year":"2004","unstructured":"Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J, Ingalls KA, Perez EA, Ingle JN, Couch FJ, Visscher DW (2004) Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol 17:756\u2013764","journal-title":"Mod Pathol"},{"key":"778_CR50","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"778_CR51","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0960-9776(03)80158-3","volume":"12","author":"HT Mouridsen","year":"2003","unstructured":"Mouridsen HT, Rose C, Brodie AH, Smith IE (2003) Challenges in the endocrine management of breast cancer. Breast 12(Suppl 2):S2\u2013S19","journal-title":"Breast"},{"key":"778_CR52","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1158\/0008-5472.CAN-08-0538","volume":"68","author":"A Naresh","year":"2008","unstructured":"Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE (2008) The HER4\/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68:6387\u20136395","journal-title":"Cancer Res"},{"key":"778_CR53","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1200\/JCO.1992.10.5.696","volume":"10","author":"AM Neville","year":"1992","unstructured":"Neville AM, Bettelheim R, Gelber RD, Gelber RD, S\u00e4ve-S\u00f6derbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN (1992) Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 10:696\u2013705","journal-title":"J Clin Oncol"},{"key":"778_CR54","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00595-005-3056-x","volume":"35","author":"H Okugawa","year":"2005","unstructured":"Okugawa H, Yamamoto D, Uemura Y, Sakaida N, Yamada M, Tanaka K, Kamiyama Y (2005) Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution. Surg Today 35:907\u2013911","journal-title":"Surg Today"},{"key":"778_CR55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1992.10.5.679","volume":"10","author":"CK Osborne","year":"1992","unstructured":"Osborne CK (1992) Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10:679\u2013682","journal-title":"J Clin Oncol"},{"key":"778_CR56","first-page":"4217","volume":"6","author":"V Pawlowski","year":"2000","unstructured":"Pawlowski V, R\u00e9villion F, Hebbar M, Hornez L, Peyrat JP (2000) Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription\u2013polymerase chain reaction assay. Clin Cancer Res 6:4217\u20134225","journal-title":"Clin Cancer Res"},{"key":"778_CR57","first-page":"2435","volume":"10","author":"RJ Pietras","year":"1995","unstructured":"Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435\u20132446","journal-title":"Oncogene"},{"key":"778_CR58","first-page":"1829","volume":"9","author":"RJ Pietras","year":"1994","unstructured":"Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ (1994) Antibody to HER-2\/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829\u20131838","journal-title":"Oncogene"},{"key":"778_CR59","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa054504","volume":"354","author":"K Pritchard","year":"2006","unstructured":"Pritchard K, Shepherd LE, O\u2019Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN, National Cancer Institute of Canada Clinical Trials Group (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103\u20132111","journal-title":"N Engl J Med"},{"key":"778_CR60","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","volume":"19","author":"PM Ravdin","year":"2001","unstructured":"Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980\u2013991","journal-title":"J Clin Oncol"},{"key":"778_CR61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF01840835","volume":"22","author":"JF Robertson","year":"1992","unstructured":"Robertson JF, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW (1992) Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Res Treat 22:221\u2013227","journal-title":"Breast Cancer Res Treat"},{"key":"778_CR62","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000227037","volume":"49","author":"M Robinovich","year":"1992","unstructured":"Robinovich M, Vallejo C, Bianco A, Perez J, Machiavelli M, Leone B, Romero A, Rodriguez R, Cuevas M, Dansky C, Xynos F, Alvarez L (1992) Development and validation of prognostic models in metastatic breast cancer: a GOCS Study. Oncology 49:188\u2013195","journal-title":"Oncology"},{"key":"778_CR63","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1200\/JCO.1993.11.11.2090","volume":"11","author":"PP Rosen","year":"1993","unstructured":"Rosen PP, Groshen S, Kinne DW, Norton L (1993) Factors influencing prognosis in node negative breast carcinoma: analysis of 767 TINOMO\/T2NOMO patients with long term follow-up. J Clin Oncol 11:2090\u20132100","journal-title":"J Clin Oncol"},{"key":"778_CR64","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirz\u00e9n F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"778_CR65","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","volume":"26","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672\u20134678","journal-title":"J Clin Oncol"},{"key":"778_CR66","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2005.04.4420","volume":"24","author":"FA Shepherd","year":"2006","unstructured":"Shepherd FA, Tsao MS (2006) Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24:1219\u20131220","journal-title":"J Clin Oncol"},{"key":"778_CR67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.breast.2003.08.007","volume":"13","author":"A Sidoni","year":"2004","unstructured":"Sidoni A, Bellezza G, Cavaliere A, Del Sordo R, Scheibel M, Bucciarelli E (2004) Prognostic indexes in breast cancer: comparison of the Nottingham and Adelaide indexes. Breast 13:23\u201327","journal-title":"Breast"},{"key":"778_CR68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"778_CR69","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.1996.14.8.2191","volume":"14","author":"GW Sledge Jr","year":"1996","unstructured":"Sledge GW Jr (1996) Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer. J Clin Oncol 14:2191\u20132193","journal-title":"J Clin Oncol"},{"key":"778_CR70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10549-007-9556-1","volume":"107","author":"I Soerjomataram","year":"2008","unstructured":"Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107:309\u2013330","journal-title":"Breast Cancer Res Treat"},{"key":"778_CR71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2407-9-13","volume":"9","author":"YF Sun","year":"2009","unstructured":"Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ (2009) Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 9:13","journal-title":"BMC Cancer"},{"key":"778_CR72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.1003","volume":"196","author":"Z Suo","year":"2002","unstructured":"Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM (2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196:17\u201325","journal-title":"J Pathol"},{"key":"778_CR73","first-page":"1552","volume":"39","author":"KD Swenerton","year":"1979","unstructured":"Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552\u20131562","journal-title":"Cancer Res"},{"key":"778_CR74","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.3816\/CBC.2009.s.007","volume":"9","author":"ML Telli","year":"2009","unstructured":"Telli ML, Carlson RW (2009) First-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 9:S66\u2013S72","journal-title":"Clin Breast Cancer"},{"key":"778_CR75","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1442-2050.2006.00622.x","volume":"19","author":"D Vallb\u00f6hmer","year":"2006","unstructured":"Vallb\u00f6hmer D, Lenz HJ (2006) Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 19:425\u2013432","journal-title":"Dis Esophagus"},{"key":"778_CR76","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1634\/theoncologist.12-7-785","volume":"12","author":"S Verma","year":"2007","unstructured":"Verma S, Clemons M (2007) First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 12:785\u2013797","journal-title":"Oncologist"},{"key":"778_CR77","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","volume":"5","author":"J Verweij","year":"1994","unstructured":"Verweij J, Clavel M, Chevalier B (1994) Paclitaxel (Taxol\u2122) and docetaxel (Taxotere\u2122): not simply two of a kind. Ann Oncol 5:495\u2013505","journal-title":"Ann Oncol"},{"key":"778_CR78","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","volume":"7","author":"GA Viani","year":"2007","unstructured":"Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment f HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153\u2013163","journal-title":"BMC Cancer"},{"key":"778_CR79","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719\u2013726","journal-title":"J Clin Oncol"},{"key":"778_CR80","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(05)17947-1","volume":"365","author":"Y Wang","year":"2005","unstructured":"Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671\u2013679","journal-title":"Lancet"},{"key":"778_CR81","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/bjs.1800730925","volume":"73","author":"MR Williams","year":"1986","unstructured":"Williams MR, Todd JH, Nicholson RI, Elston CW, Blamey RW, Griffiths K (1986) Survival patterns in hormone treated advanced breast cancer. Br J Surg 73:752\u2013755","journal-title":"Br J Surg"},{"key":"778_CR82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1991.103","volume":"63","author":"J Winstanley","year":"1991","unstructured":"Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS (1991) The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63:447\u2013450","journal-title":"Br J Cancer"},{"key":"778_CR83","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","volume":"200","author":"CJ Witton","year":"2003","unstructured":"Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1\u20134 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290\u2013297","journal-title":"J Pathol"},{"key":"778_CR84","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"778_CR85","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1998.16.7.2401","volume":"16","author":"N Yamamoto","year":"1998","unstructured":"Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Takue Y, Narabayashi M, Adachi I, Takashima S (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16:2401\u20132408","journal-title":"J Clin Oncol"},{"key":"778_CR86","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bjc.6602469","volume":"92","author":"KH Yeh","year":"2005","unstructured":"Yeh KH, Lu YS, Hsu CH, Lin JF, Chao HJ, Huang TC, Chung CY, Chang CS, Yang CH, Cheng AL (2005) Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer. Br J Cancer 92:1013\u20131018","journal-title":"Br J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0778-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-009-0778-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-009-0778-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T15:26:33Z","timestamp":1590247593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-009-0778-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,11]]},"references-count":86,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s00520-009-0778-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,11]]}}}